Question · Q3 2025
Leonid Timoshev asked about the differences between NT2 and IH populations, the ability to accurately capture them in separate trials, physician diagnostic practices, and the impact on their relative market opportunities.
Answer
Richard Pops, CEO, stated that the full answer will be known after completing both studies, acknowledging potential regional differences in diagnosis. He highlighted the de novo nature of the clinical research for orexin-2 receptor agonists in these populations and the value of phase two data for informing phase three design, noting that patients are currently enrolled without discrimination.